We use therm - cardioprotective drugs, cardioprotective medications, drug with cardioprotective property... But what medications we should name as cardioprotective...
- that limit damage to the heart muscle cells or - such drugs have the potential to preserve the pumping ability of the heart or - delaying the onset of heart failure or - reducing deaths?
Since 1984 we use word - cardioprotection...
In my opinion - cardioprotection - prevention, delay or reduction of myocardial injury, especially that caused by ischemia.
Book Review – Cardioprotection
For more than 30 years, the term ‘cardioprotection’ has been applied widely and often without precision to sundry interventions that reduce the incidence and severity of cardiovascular disease. For those of us who spend time occluding and reperfusing coronary arteries to model experimentally the effects of coronary thrombosis, ‘cardioprotection’ has a precise (and arguably the definitive) meaning; i.e. cardioprotection is the limitation or prevention of irreversible cellular injury in heart muscle as a consequence of ischaemia and reperfusion. In this little book, this definition is applied and is extended to consider all aspects of the medical management of acute myocardial infarction. This is a highly successful and justified approach that will maximise the appeal and utility of this text to a wide clinical and scientific audience. Barely 120 pages of text, nevertheless the book provides an up-to-date and remarkably comprehensive series of essays that convey an accurate snapshot of the basic and clinical science relevant to the rational treatment of myocardial infarction.
For >4 decades, the holy grail in the treatment of acute myocardial infarction has been the mitigation of lethal injury. Despite promising initial results and decades of investigation by the cardiology research community, the only treatment with proven efficacy is early reperfusion of the occluded coronary artery. The remarkable record of failure has led us and others to wonder if cardioprotection is dead. The path to translation, like the ascent to Everest, is certainly littered with corpses. We do, however, highlight a therapeutic principle that provides a glimmer of hope: cellular postconditioning. Administration of cardiosphere-derived cells after reperfusion limits infarct size measured acutely, while providing long-term structural and functional benefits. The recognition that cell therapy may be cardioprotective, and not just regenerative, merits further exploration before we abandon the pursuit entirely.
Article Is Cardioprotection Dead?
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs